Asklepios BioPharmaceutical, Inc.
https://www.askbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Asklepios BioPharmaceutical, Inc.
CGT Is In Its Infancy For CNS Disorders, But Technical Strides Being Made
Technical challenges and lackluster investor sentiment about the near-term commercial potential of cell and gene therapies in neurological disorders may be holding the field back.
Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs
The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.
Takeda Chooses Belief For First Commercial Gene Therapy Tie-Up In China
A new gene therapy deal between Takeda and Belief signals multinationals are continuing to increase the pace of collaboration with Chinese partners as a source of innovation.
Bayer Bids To Become Cell Therapy Manufacturing Leader
The German group has invested $250m into a facility at its campus in Berkeley, CA to produce cell therapies from its own portfolio and for other companies in the space who are looking to tackle the perennial issue of manufacturing.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- Actus Therapeutics, Inc.
- AskBio
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
- BrainVectis
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice